HIV TESTING AND TREATMENT TO PREVENT ONWARD HIV TRANSMISSIONAMONG MSM AND TRANSGENDER WOMEN IN LIMA, PER

Centro de Investigacion del Cancer Fred Hutchinson, Estados Unidos,0 sites2,138 target enrollmentMarch 27, 2015

Overview

Phase: N/A
Intervention: Not specified
Conditions: Not specified
Sponsor: Centro de Investigacion del Cancer Fred Hutchinson, Estados Unidos,
Enrollment: 2138
Status: Recruiting
Last Updated: 2 years ago

No summary available.

Registry

who.int

Start Date

March 27, 2015

End Date

October 15, 2019

Last Updated

2 years ago

Study Type

Interventional

Sex

Male

Sponsor

Centro de Investigacion del Cancer Fred Hutchinson, Estados Unidos,

•In Step 1, potential participants must be MSM and transgender women , have sex with men,
•HIV status, at high\-risk for HIV acquisition. Each potential participant must have the ability and
•willingness to provide informed consent for study participation, including being tested for HIV\-1\.
•If HIV infection is not diagnosed, he must be willing to be enrolled in Step 2, and if diagnosed
•with acute or recent HIV infection be willing to consider participation in Step 3\. In particular, if
•they are HIV seronegative on antibodies analysis, but with evidence of acute infection (HIV\-1
•RNA\-positive confirmed by HIV antigen analysis), they should be willing to be re\-contacted for
•further HIV testing and linkage to care.
•In Step 2, volunteers who were found to have no HIV infection from Step 1 will be re\-tested at
•variable times for incident HIV\-1\. Roughly, we anticipate testing 800 MSM and transgender

•1\. Any medical, psychological/psychiatric, occupational, or other condition that, in the
•judgment of the investigator, would interfere with, or serve as a contraindication to,
•protocol adherence, assessment of safety, or a participant’s ability to give informed
•2\. Seeking HIV test behavior for routine reasons.
•3\. Use of estrogens (or its derivatives) or anti\-androgens, administered orally or intramuscularly,
•during the past three months.
•Any medical, psychological/psychiatric, occupational, or other condition that, in the judgment of
•the investigator, would interfere with, or serve as a contraindication to, protocol adherence,
•assessment of safety, or a participant’s ability to give informed consent;
•1\. Presentation with WHO clinical stage 3 or 4 irrespective of CD4 count.